<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="addendum" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Rare Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Rare Dis</journal-id>
<journal-id journal-id-type="publisher-id">KRAD</journal-id>
<journal-id journal-id-type="publisher-id">krad20</journal-id>
<journal-title-group>
<journal-title>Rare Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">2167-5511</issn>
<publisher>
<publisher-name>Taylor &amp; Francis</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28032012</article-id>
<article-id pub-id-type="pmc">5154382</article-id>
<article-id pub-id-type="publisher-id">1220468</article-id>
<article-id pub-id-type="doi">10.1080/21675511.2016.1220468</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Addendum</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurodevelopmental models of transcription factor 4 deficiency converge on a
common ion channel as a potential therapeutic target for Pitt Hopkins
syndrome</article-title>
<alt-title alt-title-type="running-authors">M. D. RANNALS ET AL.</alt-title>
<alt-title alt-title-type="running-title">RARE DISEASES</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rannals</surname>
<given-names>Matthew D.</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Page</surname>
<given-names>Stephanie Cerceo</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Campbell</surname>
<given-names>Morganne N.</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gallo</surname>
<given-names>Ryan A.</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mayfield</surname>
<given-names>Brent</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maher</surname>
<given-names>Brady J.</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="af0004">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="an0001"></xref>
</contrib>
<aff id="af0001"><label>a</label><institution>Department of Neurobiology, School of
Medicine, University of Pittsburgh</institution>, Pittsburgh, PA,
<country>USA</country></aff>
<aff id="af0002"><label>b</label><institution>Lieber Institute for Brain Development, Johns
Hopkins Medical Campus</institution>, Baltimore, MD, <country>USA</country></aff>
<aff id="af0003"><label>c</label><institution>Department of Psychiatry and Behavioral
Sciences, Johns Hopkins School of Medicine</institution>, Baltimore, MD,
<country>USA</country></aff>
<aff id="af0004"><label>d</label><institution>Department of Neuroscience, Johns Hopkins
School of Medicine</institution>, Baltimore, MD, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="an0001"><bold>CONTACT</bold> Brady J. Maher <email xlink:href="brady.maher@libd.org">brady.maher@libd.org</email><institution>Lieber Institute for Brain Development</institution>, <addr-line>855 N. Wolfe
St.</addr-line>, Baltimore, MD 21205, <country>USA</country></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>5</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>5</day>
<month>8</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>4</volume>
<issue>1</issue>
<elocation-id seq="1">e1220468</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="description"> &#x000a9; Matthew D. Rannals, Stephanie Cerceo
          Page, Morganne N. Campbell, Ryan A. Gallo, Brent Mayfield, and Brady J.
          Maher <copyright-statement>-->
<copyright-statement>© 2016 The Author(s). Published with license by Taylor &amp;
Francis Group, LLC</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>The Author(s)</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution-Non-Commercial License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited. The moral rights of the named author(s) have been
asserted.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="krad-04-01-1220468.pdf"></self-uri>
<related-article ext-link-type="doi" id="d37e196" related-article-type="addended-article" xlink:href="10.1016/j.neuron.2016.02.021">Addendum to: <person-group person-group-type="author"><name name-style="western"><surname>Rannals</surname><given-names>MD</given-names></name></person-group>
<article-title>Psychiatric risk gene transcription factor 4 regulates intrinsic excitability
of prefrontal neurons via repression of SCN10a and KCNQ1</article-title>.
<source/>Neuron
<year>2016</year>; <volume>90</volume>:<fpage>43</fpage>-<lpage>55</lpage>; PMID: ; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.neuron.2016.02.021</pub-id></related-article>
<abstract>
<title>ABSTRACT</title>
<p>The clinically pleiotropic gene, Transcription Factor 4 (TCF4), is a broadly expressed
basic helix-loop-helix (bHLH) transcription factor linked to multiple neurodevelopmental
disorders, including schizophrenia, 18q deletion syndrome, and Pitt Hopkins syndrome
(PTHS). <italic>In vivo</italic> suppression of <italic>Tcf4</italic> by shRNA or mutation
by CRISPR/Cas9 in the developing rat prefrontal cortex resulted in attenuated action
potential output. To explain this intrinsic excitability deficit, we demonstrated that
haploinsufficiency of TCF4 lead to the ectopic expression of two ion channels,
<italic>Scn10a</italic> and <italic>Kcnq1</italic>. These targets of TCF4 regulation
were identified through molecular profiling experiments that used translating ribosome
affinity purification to enrich mRNA from genetically manipulated neurons.</p>
<p>Using a mouse model of PTHS (<italic>Tcf4</italic><sup>+/tr</sup>), we observed a
similar intrinsic excitability deficit, however the underlying mechanism appeared slightly
different than our rat model - as <italic>Scn10a</italic> expression was similarly
increased but <italic>Kcnq1</italic> expression was decreased. Here, we show that the
truncated TCF4 protein expressed in our PTHS mouse model binds to wild-type TCF4 protein,
and we suggest the difference in <italic>Kcnq1</italic> expression levels between these
two rodent models appears to be explained by a dominant-negative function of the truncated
TCF4 protein. Despite the differences in the underlying molecular mechanisms, we observed
common underlying intrinsic excitability deficits that are consistent with ectopic
expression of <italic>Scn10a</italic>. The converging molecular function of TCF4 across
two independent rodent models indicates SCN10a is a potential therapeutic target for
Pitt-Hopkins syndrome.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>autism</kwd>
<kwd>Ion channels</kwd>
<kwd>KCNQ1</kwd>
<kwd>Pitt-Hopkins syndrome</kwd>
<kwd>schizophrenia</kwd>
<kwd>SCN10a</kwd>
<kwd>TCF4</kwd>
<kwd>transcription factor</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="0"></table-count>
<ref-count count="23"></ref-count>
<page-count count="5"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s0001" sec-type="intro">
<title>Introduction</title>
<p>Pitt Hopkins syndrome (PTHS) is a rare, pervasive developmental disorder resulting from
autosomal dominant mutations on chromosome 18 at the <italic>TCF4</italic> (<italic>ITF2,
SEF2, E2-2</italic>) locus that lead to TCF4 haploinsufficiency and/or a dominant-negative
mechanism.<xref ref-type="bibr" rid="cit0001"><sup>1-4</sup></xref> PTHS shares neurodevelopmental characteristics with the 18q
deletion syndrome including cognitive and motor learning deficits, a lack of language
acquisition, stereotypical autistic behaviors, epilepsy, and breathing abnormalities.<xref ref-type="bibr" rid="cit0005"><sup>5-8</sup></xref> In addition,
common variation within and around the <italic>TCF4</italic> gene is genome-wide significant
for association with risk for schizophrenia<xref ref-type="bibr" rid="cit0009"><sup>9,10</sup></xref> as well as for cognitive endophenotypes linked to
schizophrenia.<xref ref-type="bibr" rid="cit0011"><sup>11,12</sup></xref>
Therefore understanding the impact of TCF4 dysfunction on brain development and function
will be important for delineating the molecular mechanisms that drive the underlying
pathophysiologies in PTHS.</p>
<p>Here we summarize our novel approach to identifying these molecular mechanisms that link
genetic dysfunction of TCF4 to functional deficits in neurodevelopment. Using both an
<italic>in utero</italic> gene transfer model to identify cell autonomous effects of TCF4
dysfunction and a PTHS mouse model, we were able to determine specific electrophysiological
phenotypes that consist of deficits in neuronal excitability and action potential (AP)
output.<xref ref-type="bibr" rid="cit0013"><sup>13</sup></xref> Furthermore, our approach
utilized recently developed molecular profiling techniques that involve immunoprecipitating
mRNA that is actively being translated by ribosomal complexes, thus giving us access to the
translatome of a given target cell population.<xref ref-type="bibr" rid="cit0014"><sup>14,15</sup></xref> The combined set of experimental techniques we describe is well
suited for phenotypic discovery and for the identification of molecular mechanisms that can
ultimately be targeted for potential therapeutic benefit. We believe this is an attractive
experimental strategy that can be applied to other disorders of neurodevelopment and rare
diseases affecting the brain.</p>
</sec>
<sec id="s0002">
<title><italic>In vivo</italic> cell autonomous model of PTHS</title>
<p>In order to gain insight into the prominent neurodevelopmental characteristics of PTHS, we
sought to model the disease <italic>in vivo</italic>. This was accomplished by developing an
<italic>in vivo</italic> cell-autonomous model of the disease through TCF4 gene expression
knockdown in the medial prefrontal cortex (mPFC) of the rat.<xref ref-type="bibr" rid="cit0013"><sup>13</sup></xref> Two shRNA constructs targeting <italic>Tcf4</italic>
(shTCF4) were separately transfected by <italic>in utero</italic> electroporation (IUE) to
knockdown expression in layer 2/3 pyramidal neurons of developing embryos. Each shRNA, one
targeting a common 3′ exon in all <italic>Tcf4</italic> isoforms and the other
targeting a common 3′ UTR, resulted in a significant reduction of TCF4 protein. We
observed that expression of shTCF4 produced no gross morphological deficits, but resulted in
a clear reduction in spike frequency output compared to a control shRNA (shCon). A rescue of
AP output was achieved by overexpression of the human TCF4B isoform along with an shRNA,
providing evidence that intrinsic excitability deficits represent a sequence-dependent
effect. Although this phenotype was replicated across both shRNA experiments, we further
validated the observation by delivering a CRISPR-Cas9 construct to target
<italic>Tcf4</italic>, thus controlling for sequence-independent off-target effects. The
crTCF4 also resulted in a significantly reduced neuronal spike frequency, showing the
disruption of TCF4-dependent signaling directly contributes to a deficit in intrinsic
neuronal excitability.</p>
</sec>
<sec id="s0003">
<title>Targeted molecular profiling</title>
<p>Translating ribosome affinity purification (TRAP) is a targeted molecular profiling method
that has previously been used to identify cell type-specific mRNA expression that gives rise
to the unique molecular profiles of different populations of neurons in the CNS.<xref ref-type="bibr" rid="cit0016"><sup>16</sup></xref> We adapted TRAP to our IUE model in a
novel approach we term iTRAP. Our adapted protocol includes co-expression of an EGFP-fused
L10a ribosomal protein (L10a-EGFP) along with either shRNA or shCon constructs during IUE.
Transfected mPFC tissue from P21 animals was affinity purified to isolate mRNA associated
with active translation at the ribosome at the time of sample capture.<xref ref-type="bibr" rid="cit0013"><sup>13</sup></xref></p>
<p>This method provides multiple advantages in answering our specific questions about the
underlying mechanism behind the phenotype generated in our IUE model of PTHS. IUE has
several distinctive advantages as a model, including the high fidelity of co-transfection of
multiple plasmids, as well as temporal and spatial specificity of cell-types that are
transfected. In addition, the relatively sparse expression pattern that results is ideal for
identifying cell-autonomous phenotypes that result from the specific genetic manipulation
employed.<xref ref-type="bibr" rid="cit0017"><sup>17,18</sup></xref> However, the
mosaic expression pattern prevents the use of bulk tissue to assay protein or mRNA levels
since the majority of cells are untransfected. Indeed, we found that mRNA measured from bulk
shRNA or control homogenates was insufficient to produce a measurable differential
expression of ion channels responsible for intrinsic excitability deficits.<xref ref-type="bibr" rid="cit0013"><sup>13</sup></xref> However, the enrichment of mRNA from
transfected cells by iTRAP allowed us to identify significant upregulation in the
translation of target ion channels that were shown to ultimately be responsible for the
observed excitability deficit.</p>
</sec>
<sec id="s0004">
<title>Reduced TCF4 causes ectopic expression of ion channels</title>
<p>The differential expression between shTCF4 and shCon neurons indicated that two ion
channels, <italic>Kcnq1</italic> and <italic>Scn10a</italic>, were at least partially
responsible for the excitability phenotype due to TCF4 haploinsufficiency. Translation of
these two ion channels were found to be significantly upregulated in the shTCF4 condition
when profiled using a prefabricated PCR plate containing primers for all known rat ion
channel genes. Additionally, genomic DNA close to each of these two ion channels was
confirmed to be directly bound by TCF4 through the analysis of multiple independent TCF4
ChIP-seq data sets.<xref ref-type="bibr" rid="cit0019"><sup>19</sup></xref></p>
<p>The specificity of these signals was confirmed by multiple pharmacological and molecular
experiments in order to validate the biological relevance of these ion channels as
downstream effectors of TCF4 initiated pathophysiology. Antagonists to both KCNQ1 (UCL2077
and JNJ303) and SCN10a (A-803467) were capable of rescuing spike frequency output in shTCF4
neurons while having no effect on shCon cells. Overexpression of a recombinant Scn10a
resulted in a phenocopy of excitability deficits of TCF4 knockdown. Lastly, co-expression of
CRISPR-Cas9 constructs targeting both <italic>Kcnq1</italic> and <italic>Scn10a</italic>
along with the shTCF4 resulted in a complete rescue of AP output. Thus, molecular profiling
by iTRAP resulted in a remarkable advance in identifying biologically relevant mechanisms
underpinning the TCF4 haploinsufficiency phenotype, a result unlikely to be achieved using
traditional pharmacological methods in a comparable timeframe.</p>
</sec>
<sec id="s0005">
<title>Mouse model of PTHS</title>
<p>Having found convincing evidence of ion channel regulation by TCF4, we sought to confirm
these observations in an additional rodent model of PTHS. Using a mouse model initially
generated to produce haploinsufficiency of TCF4 through constitutive germline deletion of
one <italic>Tcf4</italic> gene allele,<xref ref-type="bibr" rid="cit0020"><sup>20</sup></xref> we repeated measurements of intrinsic neuronal excitability through
whole-cell recordings of layer 2/3 cortical neurons and observed a similar reduction in
spike output compared to control littermates. Surprisingly, through western blot analysis of
our PTHS mouse model, we determined that instead of the targeted constitutive
<italic>Tcf4</italic> deletion, a truncated TCF4 protein was expressed and this indicated
the possibility that this transgenic mouse was instead a dominant-negative model.<xref ref-type="bibr" rid="cit0004"><sup>4</sup></xref> Therefore, we originally speculated that
expression of a truncated TCF4 protein could be one explanation for the ion channel
expression differences we observed between our <italic>in utero</italic> TCF4 knockdown
models and this PTHS mouse model.</p>
</sec>
<sec id="s0006">
<title>Transcriptional control of TCF4</title>
<p>In the PTHS patient population, both large deletions of the entire gene and single point
mutations within the bHLH are observed,<xref ref-type="bibr" rid="cit0001"><sup>1-3</sup></xref> and both haploinsufficiency and dominant-negative models have
been posited.<xref ref-type="bibr" rid="cit0004"><sup>4</sup></xref> Therefore, this PTHS
mouse model is relevant regardless of whether it is a haploinsufficiency or
dominant-negative model. However, to understand underlying molecular mechanisms downstream
of TCF4 dysfunction it is critical to determine which model is being employed. To determine
if the truncated TCF4 protein expressed in our PTHS mouse model could result in a
dominant-negative effect, we tested its ability to bind to full-length TCF4. We PCR cloned
both the full-length and truncated cDNA from our PTHS mouse model and added different
N-terminal tags to each of the recombinant genes, where they would be predicted to not
interfere with the bHLH domain of the protein. We co-transfected these constructs into
HEK293T cells and performed co-immunoprecipitation experiments. As shown in <xref ref-type="fig" rid="f0001">Figure 1</xref>, HA-tagged full-length TCF4 (HA-mTCF4fl,
red) can pulldown Myc-tagged truncated TCF4 protein (Myc-mTCF4tr, green). This protein
pulldown experiment, in conjunction with previously reported evidence of dominant negative
effects,<xref ref-type="bibr" rid="cit0004"><sup>4</sup></xref> indicates that a
dominant-negative effect of the truncated TCF4 protein expressed in our PTHS mouse model is
a probable explanation for the mRNA expression differences between our two rodent models.
However, we still cannot completely rule out other possible explanations such as non-cell
autonomous effects that are specific to the mouse model or that the truncated TCF4 protein
has other unknown <italic>in vivo</italic> functions beyond being a dominant-negative. <fig id="f0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>HA-mTCF4fl can co-immunprecipitate Myc-mTCF4tr protein. Red indicates anti-HA
antibodies and green indicates anti-Myc antibodies. The anti-HA antibody produces a
background band in all input lanes that has a smaller molecular weight than mTCF4tr
and is not observed in the co-IP lane.</p></caption><graphic specific-use="web-only" xlink:href="krad-04-01-1220468-g001"></graphic></fig>
</p>
<p>This evidence of a dominant-negative pathological mechanism in the mouse model now further
confirms that while the cellular and molecular mechanisms involved in TCF4 regulation may be
context specific, the replicated deficit in intrinsic excitability and AP spiking output is
likely to be a true pathophysiological consequence of PTHS that is consistent across
individuals with either haploinsufficient or dominant-negative versions of the disorder.
Although <italic>Kcnq1</italic> expression diverged, <italic>Scn10a</italic> expression was
consistent between our models and the SCN10A antagonist A-803467 was effective at acutely
rescuing AP output in the TCF4<sup>+/tr</sup> mouse neurons, just as it did in the
<italic>in utero</italic> shTCF4 rat model. Our results clearly position
<italic>Scn10a</italic> as a high priority target with therapeutic potential in PTHS, as
multiple independent experimental methods all suggest that its ectopic expression is linked
to the intrinsic excitability deficit resulting from TCF4 dysfunction.</p>
</sec>
<sec id="s0007">
<title>Future directions</title>
<p>The cellular, molecular, and behavioral analysis of TCF4 in relation to PTHS is in
relatively early stages of study. TCF4 is expressed in a variety of cell types throughout
the body and it is estimated that it regulates hundreds to thousands of different genes.
Therefore, it is very likely that a variety of phenotypes, beyond just the intrinsic
excitability deficits we have observed so far, will be discovered in the near future. This
is the case for other models of autism spectrum disorders, where deficits in cell
proliferation, differentiation, synapse formation, and plasticity are observed within and
across different model systems.<xref ref-type="bibr" rid="cit0021"><sup>21-23</sup></xref> Therefore, it will be important to further characterize models
of PTHS during all stages of development and with a variety of cellular, molecular and
behavioral techniques. In addition, it will be important for the field to perform unbiased
whole genome RNA sequencing from PTHS models to aid in the identification of genes that are
both regulated by TCF4 and whose expression is disrupted in PTHS, as these regulated genes
could represent therapeutic targets. However, given the context-dependence of TCF4, it may
be critical to use cell-type specific RNA purification approaches, such as iTRAP, to obtain
better mechanistic insight into newly observed phenotypes.</p>
</sec>
<sec id="s0008" sec-type="conclusions">
<title>Conclusions</title>
<p>Determining the underlying mechanisms of pathophysiology for rare diseases, as well as for
more common disorders, is a formidable challenge. Here, and in our recent article,<xref ref-type="bibr" rid="cit0013"><sup>13</sup></xref> we have described a system for
phenotype discovery in a rare disease model that utilizes a novel molecular profiling method
we term iTRAP that is capable of identifying candidate molecular mechanisms underlying
pathophysiological phenotypes.</p>
<p>By comparing a cell autonomous TCF4 haploinsufficiency rat model to a PTHS mouse model, we
identified a common electrophysiological phenotype that is at least partially caused by
inappropriate expression of Scn10a, a voltage-gated sodium channel. We now consider SCN10a
to be a potential therapeutic target for PTHS. Further experiments are required to determine
if these phenotypes and molecular mechanisms observed at the cellular level can be
successfully translated to the level of mouse behavior, to human biology, and ultimately to
the development of therapeutic agents.</p>
</sec>
</body>
<back>
<sec>
<title>Disclosure of potential conflicts of interest</title>
<p>No potential conflicts of interest were disclosed.</p>
</sec>
<sec>
<title>Funding</title>
<p>This work was supported by NIH grant (R56MH104593) and Pitt-Hopkins Research Foundation
Award to B.J.M.</p>
</sec>
<ref-list>
<title>Bibliography</title>
<ref id="cit0001">
<label>[1]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brockschmidt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Filippi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Charbel
Issa</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nelles</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Urbach</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Eter</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Driever</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>RG</given-names></name></person-group>. <article-title>Neurologic
and ocular phenotype in Pitt-Hopkins syndrome and a zebrafish model</article-title>.
<source/>Hum. Genet
<year>2011</year>; <volume>130</volume>:<fpage>645</fpage>-<lpage>55</lpage>; PMID:21544580<pub-id pub-id-type="pmid">21544580</pub-id></mixed-citation>
</ref>
<ref id="cit0002">
<label>[2]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zweier</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sticht</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bijlsma</surname><given-names>EK</given-names></name>,
<name name-style="western"><surname>Clayton-Smith</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Boonen</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Fryer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Greally</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>L</given-names></name>, <name name-style="western"><surname>den
Hollander</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Jongmans</surname><given-names>M</given-names></name>, et al.</person-group>
<article-title>Further delineation of Pitt-Hopkins syndrome: phenotypic and genotypic
description of 16 novel patients</article-title>. <source/>J Med Genet
<year>2008</year>; <volume>45</volume>:<fpage>738</fpage>-<lpage>44</lpage>; PMID:18728071<pub-id pub-id-type="pmid">18728071</pub-id></mixed-citation>
</ref>
<ref id="cit0003">
<label>[3]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amiel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>de Pontual</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Redon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Malan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Boddaert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Plouin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Lyonnet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Munnich</surname><given-names>A</given-names></name>, et al.</person-group>
<article-title>Mutations in TCF4, encoding a class I basic helix-loop-helix transcription
factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy
associated with autonomic dysfunction</article-title>. <source/>Am J Hum Genet
<year>2007</year>; <volume>80</volume>:<fpage>988</fpage>-<lpage>93</lpage>; PMID:17436254; http://dx.doi.org/<pub-id pub-id-type="doi">10.1086/515582</pub-id><pub-id pub-id-type="pmid">17436254</pub-id></mixed-citation>
</ref>
<ref id="cit0004">
<label>[4]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepp</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pruunsild</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Timmusk</surname><given-names>T</given-names></name></person-group>. <article-title>Pitt-Hopkins
syndrome-associated mutations in TCF4 lead to variable impairment of the transcription
factor function ranging from hypomorphic to dominant-negative effects</article-title>.
<source/>Hum Mol Genet
<year>2012</year>; <volume>21</volume>:<fpage>2873</fpage>-<lpage>88</lpage>; PMID:22460224; http://dx.doi.org/<pub-id pub-id-type="doi">10.1093/hmg/dds112</pub-id><pub-id pub-id-type="pmid">22460224</pub-id></mixed-citation>
</ref>
<ref id="cit0005">
<label>[5]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whalen</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Héron</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gaillon</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Moldovan</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Devillard</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Giuliano</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Soares</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Mathieu-Dramard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Afenjar</surname><given-names>A</given-names></name>, et al.</person-group>
<article-title>Novel comprehensive diagnostic strategy in Pitt-Hopkins syndrome: Clinical
score and further delineation of the TCF4 mutational spectrum</article-title>.
<source/>Hum Mutat
<year>2011</year>; <volume>33</volume>:<fpage>64</fpage>-<lpage>72</lpage>; PMID:22045651; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/humu.21639</pub-id><pub-id pub-id-type="pmid">22045651</pub-id></mixed-citation>
</ref>
<ref id="cit0006">
<label>[6]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Doyle</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Tinsley</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Waite</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Blake</surname><given-names>DJ</given-names></name></person-group>. <article-title>Functional
analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome</article-title>.
<source/>Hum Mutat
<year>2012</year>; <volume>33</volume>:<fpage>1676</fpage>-<lpage>86</lpage>; PMID:22777675; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/humu.22160</pub-id><pub-id pub-id-type="pmid">22777675</pub-id></mixed-citation>
</ref>
<ref id="cit0007">
<label>[7]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweatt</surname><given-names>JD</given-names></name></person-group>.
<article-title>Pitt-Hopkins Syndrome: intellectual disability due to loss of
TCF4-regulated gene transcription</article-title>. <source/>Exp Mol Med
<year>2013</year>; <volume>45</volume>:<fpage>e21</fpage>; PMID:23640545; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/emm.2013.32</pub-id><pub-id pub-id-type="pmid">23640545</pub-id></mixed-citation>
</ref>
<ref id="cit0008">
<label>[8]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soileau</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hasi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sebold</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>O'Donnell</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hale</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Cody</surname><given-names>JD</given-names></name></person-group>. <article-title>Adults with
chromosome 18 abnormalities</article-title>. <source/>J Genet Couns
<year>2014</year>; <volume>24</volume>:<fpage>663</fpage>-<lpage>74</lpage>; PMID:25403900; http://dx.doi.org/<pub-id pub-id-type="doi">10.1007/s10897-014-9793-5</pub-id><pub-id pub-id-type="pmid">25403900</pub-id></mixed-citation>
</ref>
<ref id="cit0009">
<label>[9]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Schizophrenia Psychiatric Genome-Wide Association Study (GWAS)
Consortium</collab></person-group>. <article-title>Genome-wide association study
identifies five new schizophrenia loci</article-title>. <source/>Nat Genet
<year>2011</year>; <volume>43</volume>:<fpage>969</fpage>-<lpage>76</lpage>; PMID:21926974; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/ng.940</pub-id><pub-id pub-id-type="pmid">21926974</pub-id></mixed-citation>
</ref>
<ref id="cit0010">
<label>[10]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Schizophrenia Working Group of the Psychiatric Genomics
Consortium</collab></person-group>. <article-title>Biological insights from 108
schizophrenia-associated genetic loci</article-title>. <source/>Nature
<year>2014</year>; <volume>511</volume>:<fpage>421</fpage>-<lpage>7</lpage>; PMID:25056061; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nature13595</pub-id><pub-id pub-id-type="pmid">25056061</pub-id></mixed-citation>
</ref>
<ref id="cit0011">
<label>[11]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quednow</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Ettinger</surname><given-names>U</given-names></name>,
<name name-style="western"><surname>Mössner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rujescu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Giegling</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Collier</surname><given-names>DA</given-names></name>,
<name name-style="western"><surname>Schmechtig</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kühn</surname><given-names>KU</given-names></name>,
<name name-style="western"><surname>Möller</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Maier</surname><given-names>W</given-names></name>, et al.</person-group>
<article-title>The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts
sensorimotor gating in schizophrenia spectrum and healthy volunteers</article-title>.
<source/>J Neurosci
<year>2011</year>; <volume>31</volume>:<fpage>6684</fpage>-<lpage>91</lpage>; PMID:21543597; http://dx.doi.org/<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0526-11.2011</pub-id><pub-id pub-id-type="pmid">21543597</pub-id></mixed-citation>
</ref>
<ref id="cit0012">
<label>[12]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>K</given-names></name>, et al.</person-group>
<article-title>Associations between TCF4 gene polymorphism and cognitive functions in
schizophrenia patients and healthy controls</article-title>.
<source/>Neuropsychopharmacology
<year>2013</year>; <volume>38</volume>:<fpage>683</fpage>-<lpage>9</lpage>; PMID:23249814; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/npp.2012.234</pub-id><pub-id pub-id-type="pmid">23249814</pub-id></mixed-citation>
</ref>
<ref id="cit0013">
<label>[13]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rannals</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Hamersky</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Briley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gallo</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Phan</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>Hyde</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Kleinman</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name>, et al.</person-group>
<article-title>Psychiatric risk gene transcription factor 4 regulates intrinsic
excitability of prefrontal neurons via repression of SCN10a and KCNQ1</article-title>.
<source/>Neuron
<year>2016</year>; <volume>90</volume>:<fpage>43</fpage>-<lpage>55</lpage>; PMID:26971948; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.neuron.2016.02.021</pub-id><pub-id pub-id-type="pmid">26971948</pub-id></mixed-citation>
</ref>
<ref id="cit0014">
<label>[14]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ramsey</surname><given-names>KE</given-names></name>,
<name name-style="western"><surname>Suárez-Fariñas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stephan</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Surmeier</surname><given-names>DJ</given-names></name>, et al.</person-group>
<article-title>A translational profiling approach for the molecular characterization of
CNS cell types</article-title>. <source/>Cell
<year>2008</year>; <volume>135</volume>:<fpage>738</fpage>-<lpage>48</lpage>; PMID:19013281; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.cell.2008.10.028</pub-id><pub-id pub-id-type="pmid">19013281</pub-id></mixed-citation>
</ref>
<ref id="cit0015">
<label>[15]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kulicke</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fenster</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Greengard</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Heintz</surname><given-names>N</given-names></name></person-group>. <article-title>Cell
type-specific mRNA purification by translating ribosome affinity purification
(TRAP)</article-title>. <source/>Nat Protoc
<year>2014</year>; <volume>9</volume>:<fpage>1282</fpage>-<lpage>91</lpage>; PMID:24810037; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nprot.2014.085</pub-id><pub-id pub-id-type="pmid">24810037</pub-id></mixed-citation>
</ref>
<ref id="cit0016">
<label>[16]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doyle</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Dougherty</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Heiman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Stevens</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bupp</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shrestha</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Doughty</surname><given-names>ML</given-names></name>, et al.</person-group>
<article-title>Application of a translational profiling approach for the comparative
analysis of CNS cell types</article-title>. <source/>Cell
<year>2008</year>; <volume>135</volume>:<fpage>749</fpage>-<lpage>62</lpage>; PMID:19013282; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.cell.2008.10.029</pub-id><pub-id pub-id-type="pmid">19013282</pub-id></mixed-citation>
</ref>
<ref id="cit0017">
<label>[17]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maher</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>LoTurco</surname><given-names>JJ</given-names></name></person-group>.
<article-title>Disrupted-in-schizophrenia (DISC1) functions presynaptically at
glutamatergic synapses</article-title>. <source/>PLoS One
<year>2012</year>; <volume>7</volume>:<fpage>e34053</fpage>; PMID:22479520; http://dx.doi.org/<pub-id pub-id-type="doi">10.1371/journal.pone.0034053</pub-id><pub-id pub-id-type="pmid">22479520</pub-id></mixed-citation>
</ref>
<ref id="cit0018">
<label>[18]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maher</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>LoTurco</surname><given-names>JJ</given-names></name></person-group> in
<source/>Neuromethods
<year>2011</year>; <fpage>113</fpage>-<lpage>128</lpage>; http://dx.doi.org/<pub-id pub-id-type="doi">10.1007/978-1-61779-533-6_6</pub-id></mixed-citation>
</ref>
<ref id="cit0019">
<label>[19]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab></person-group>. <article-title>An
integrated encyclopedia of DNA elements in the human genome</article-title>.
<source/>Nature
<year>2012</year>; <volume>489</volume>:<fpage>57</fpage>-<lpage>74</lpage>; PMID:22955616; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nature11247</pub-id><pub-id pub-id-type="pmid">22955616</pub-id></mixed-citation>
</ref>
<ref id="cit0020">
<label>[20]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weintraub</surname><given-names>H</given-names></name></person-group>. <article-title>B-lymphocyte
development is regulated by the combined dosage of three basic helix-loop-helix genes,
E2A, E2-2, and HEB</article-title>. <source/>Mol Cell Biol
<year>1996</year>; <volume>16</volume>:<fpage>2898</fpage>-<lpage>905</lpage>;
PMID:8649400; http://dx.doi.org/<pub-id pub-id-type="doi">10.1128/MCB.16.6.2898</pub-id><pub-id pub-id-type="pmid">8649400</pub-id></mixed-citation>
</ref>
<ref id="cit0021">
<label>[21]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de la Torre-Ubieta</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Won</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Geschwind</surname><given-names>DH</given-names></name></person-group>. <article-title>Advancing
the understanding of autism disease mechanisms through genetics</article-title>.
<source/>Nat Med
<year>2016</year>; <volume>22</volume>:<fpage>345</fpage>-<lpage>61</lpage>; PMID:27050589; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nm.4071</pub-id><pub-id pub-id-type="pmid">27050589</pub-id></mixed-citation>
</ref>
<ref id="cit0022">
<label>[22]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullins</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fishell</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tsien</surname><given-names>RW</given-names></name></person-group>. <article-title>Unifying
views of autism spectrum disorders: A consideration of autoregulatory feedback
loops</article-title>. <source/>Neuron
<year>2016</year>; <volume>89</volume>:<fpage>1131</fpage>-<lpage>56</lpage>; PMID:26985722; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.neuron.2016.02.017</pub-id><pub-id pub-id-type="pmid">26985722</pub-id></mixed-citation>
</ref>
<ref id="cit0023">
<label>[23]</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Greenberg</surname><given-names>ME</given-names></name></person-group>.
<article-title>Activity-dependent neuronal signalling and autism spectrum
disorder</article-title>. <source/>Nature
<year>2013</year>; <volume>493</volume>:<fpage>327</fpage>-<lpage>37</lpage>; PMID:23325215; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nature11860</pub-id><pub-id pub-id-type="pmid">23325215</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>